Acute and long-term outcomes of acute coronary syndrome in patients with hematological malignancies

Abstract Background Coronary heart disease (CHD) and cancer are the leading causes of death. Treatment outcomes have improved significantly for both disease groups. In particular, patients with hematologic malignancies (HM) have an improved prognosis. However, knowledge of the interaction between acute coronary syndrome (ACS) and HM remains poor. Objective This analysis aimed to clarify how acute coronary syndrome affects the prognosis of HM patients. Results Between January 1, 2010, and December 31, 2018, 439,716 patients with ACS insured by AOK Germany were identified, of whom 2,104 (0.5%) also had HM. Myelodysplastic/myeloproliferative disorders, lymphocytic leukemias, and plasmacytomas predominated. These patients were approximately 6 years older and more likely to have had a myocardial infarction without ST-segment elevation. These patients had more concomitant cardiovascular disease and worse NYHA stage. They were less likely to receive coronary angiography and percutaneous coronary intervention (PCI), although the number of bleeding events was not significantly increased. Hospital stay was longer. All-cause mortality was increased regardless of age. After adjustment for patient risk profile, HM was associated with worse outcomes for all endpoints studied. Conclusion Survival is lower in ACS with HM, possibly due to the fact that these patients are less likely to undergo invasive diagnostics.Mortality, MACE and re-infarctionSurvival after STEMI and NSTEMI